Alumis shares surge 86.40% in premarket after reporting preliminary phase 3 ONWARD trial data for envudeucitinib in moderate to severe plaque psoriasis.

Alumis surged 86.40% in premarket trading, as the company reported preliminary data from its phase 3 ONWARD clinical trial of envudeucitinib for moderate to severe plaque psoriasis on January 6, 2026. Alumis is an advanced biopharmaceutical company developing next-generation targeted therapies for immune-mediated diseases, with its core product being an oral TYK2 inhibitor.